Loading…
Valneva SE is projected to rise to $5.68 by 2027, a +13% move from its current price of $5.05. VALN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.95 | $5.05 | $5.16 | +0.02% |
| Jul 14 | $4.90 | $5.05 | $5.20 | +0.05% |
| Jul 15 | $4.87 | $5.05 | $5.24 | +0.07% |
| Jul 16 | $4.85 | $5.05 | $5.27 | +0.09% |
| Jul 17 | $4.82 | $5.06 | $5.30 | +0.11% |
| Jul 18 | $4.80 | $5.06 | $5.32 | +0.14% |
| Jul 19 | $4.78 | $5.06 | $5.35 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.78 | $5.06 | $5.35 | +0.16% |
| Week 2 | $4.68 | $5.07 | $5.48 | +0.32% |
| Week 3 | $4.61 | $5.07 | $5.59 | +0.48% |
| Week 4 | $4.55 | $5.08 | $5.68 | +0.65% |
| Week 5 | $4.49 | $5.09 | $5.77 | +0.81% |
| Week 6 | $4.45 | $5.10 | $5.84 | +0.97% |
| Week 7 | $4.41 | $5.11 | $5.92 | +1.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. Its product portfolio includes IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Valneva SE (VALN) is currently priced at $5.09 per share with a market capitalization of $482.65M and a rank of 3097. The current price and market position place it among smaller-cap healthcare names. The thirty-day technical picture is Bearish, with RSI14 at 30.
The 50-day simple moving average sits at $5.56 and the 200-day simple moving average sits at $8.34. Near-term support is at $5.09 and resistance at $6.34, with the stock trading in a 30-day range of $4.47 to $5.79. The longer-term forecast suggests a bullish trajectory starting later in the horizon, with the 2026 base around $5.09 on average and a path toward higher averages by 2030 and beyond, culminating in a much higher long-run outlook.
A major floor 16.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 24.8% above — a clean break opens room to run.
A major ceiling 125.5% above — clearing it would confirm fresh momentum.
Key VALN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VALN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.26 | Sell | $5.21 | Sell |
| MA 10 | $5.22 | Sell | $5.24 | Sell |
| MA 20 | $5.28 | Sell | $5.31 | Sell |
| MA 50 | $5.54 | Sell | $5.71 | Sell |
| MA 100 | $6.95 | Sell | $6.51 | Sell |
| MA 200 | $8.21 | Sell | $7.27 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.46 | Neutral |
| Stoch RSI (14) | 24.17 | Neutral |
| CCI (20) | -180.88 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -6.48 | Sell |
| Bollinger %B (20,2) | -0.07 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.33 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 37.33 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 5.25 | Sell |
| ADX (14) | 19.44 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day picture is Bearish, with RSI11? No, RSI14 = 30. The price is trading near support at $5.09 and faces resistance at $6.34. Over the last 30 days, the price has moved within a range of $4.47 to $5.79. Overall near-term momentum remains weak as the stock hovers around the $5.09 support level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.05 | $5.05 | $6.47 | 0% | Neutral | |
| $4.62 | $5.68 | $7.33 | +13% | Neutral | |
| $5.18 | $6.51 | $8.65 | +29% | Bullish | |
| $5.74 | $7.33 | $9.97 | +45% | Bullish | |
| $5.85 | $7.59 | $10.53 | +50% | Bullish | |
| $5.91 | $7.77 | $10.96 | +54% | Bullish | |
| $5.87 | $7.82 | $11.20 | +55% | Bullish | |
| $6.17 | $8.31 | $12.08 | +65% | Bullish | |
| $7.04 | $9.59 | $14.12 | +90% | Bullish | |
| $7.56 | $10.42 | $15.53 | +106% | Bullish | |
| $8.94 | $12.94 | $20.29 | +156% | Bullish | |
| $17.12 | $26.85 | $45.39 | +432% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.05 | $5.05 | $5.99 | +0.00% |
| August 2026 | $4.28 | $5.02 | $6.02 | -0.69% |
| September 2026 | $4.37 | $5.16 | $6.24 | +2.83% |
| October 2026 | $4.50 | $5.33 | $6.50 | +3.42% |
| November 2026 | $4.45 | $5.29 | $6.49 | -0.75% |
| December 2026 | $4.39 | $5.24 | $6.47 | -1.00% |
Click any year to see its month-by-month VALN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VALN is projected to trade between $5.05 and $6.47, averaging $5.05 — a potential gain of 0% from today's $5.05. Price action looks broadly range-bound.
Valneva SE's 2027 outlook centres on $5.68, within a $4.62 to $7.33 range. That is up +13% on the projected 2026 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, VALN could reach as high as $8.65, with a base case around $6.51 and support toward $5.18 — roughly +29% from $5.05. Momentum favours further upside here.
Expect VALN to range from $5.74 to $9.97 through 2029. The $7.33 average target implies a +45% move from current prices. That is up +13% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The VALN price prediction for 2030 points to an average of $7.59 (low $5.85, high $10.53) — a potential gain of +50% on today's $5.05. Momentum favours further upside here.
In 2031, VALN is projected to trade between $5.91 and $10.96, averaging $7.77 — a potential gain of +54% from today's $5.05. That is up +2% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Valneva SE's 2032 outlook centres on $7.82, within a $5.87 to $11.20 range. That is up +1% on the projected 2031 average. That marks a +55% change versus current levels. Momentum favours further upside here.
By 2033, VALN could reach as high as $12.08, with a base case around $8.31 and support toward $6.17 — roughly +65% from $5.05. Buyers look set to stay in control over this stretch.
Expect VALN to range from $7.04 to $14.12 through 2034. The $9.59 average target implies a +90% move from current prices. That is up +15% on the projected 2033 average. Momentum favours further upside here.
The VALN price prediction for 2035 points to an average of $10.42 (low $7.56, high $15.53) — a potential gain of +106% on today's $5.05. Buyers look set to stay in control over this stretch.
In 2040, VALN is projected to trade between $8.94 and $20.29, averaging $12.94 — a potential gain of +156% from today's $5.05. That is up +24% on the projected 2035 average. Momentum favours further upside here.
Valneva SE's 2050 outlook centres on $26.85, within a $17.12 to $45.39 range. That is up +108% on the projected 2040 average. That marks a +432% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in VALN today (≈ 198.019802 VALN) could be worth
$5,316.28
+$4,316.28 (+432%) by 2050 · US Dollar
Based on the average projected VALN price of $26.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VALNwould be worth at today's price.
$1,000 invested in VALN on Jul 10, 2025 (≈ 166.389345 VALN) would be worth
$840.27
-$159.73 (-16.0%) today · 0.84× · US Dollar
Based on a VALN entry price of $6.01 vs. today's $5.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.22 | $966.51 | -3.3% |
| 1 month ago | $5.26 | $960.08 | -4.0% |
| 3 months ago | $6.18 | $817.15 | -18.3% |
| 6 months ago | $9.76 | $517.42 | -48.3% |
| 1 year ago | $6.01 | $840.27 | -16.0% |
| All time (5.0y) ago | $26.24 | $192.45 | -80.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VALN forecast.
Our base-case forecast reaches $10.00 around 2035.
Implied market cap at $10.00: $1.02B
The multi-year forecast shifts from neutral in 2026–27 to bullish thereafter. In 2026 the forecast is neutral with a min of $5.09, avg $5.09, max $6.53 and ROI 0. In 2027 the forecast remains neutral with min $4.71, avg $5.77, max $7.41 and ROI 13.4.
Beginning 2028, the outlook turns bullish, with min $5.23, avg $6.53, max $8.62 and ROI 28.4; through 2029 the trend remains bullish (min $5.88, avg $7.46, max $10.06; ROI 46.6); 2030 shows a bullish path with avg $7.68 and ROI 50.9 (min $5.97, max $10.55). By 2031–2032 the averages rise further (2031 avg $7.75, 2032 avg $7.97) and continue climbing through 2033 ($8.44) and 2034 ($9.62) with rising ROI, culminating in 2050 with avg $27.24 and ROI 435.2%. The forecast also labels 2040 as bullish with avg $13.04 and ROI 156.1%, underscoring substantial upside potential by mid-century.
These are estimates, not guarantees, and depend on market and sector conditions. In summary, the long-term view points to a pronounced upside from the late 2020s into 2050, with a rising average price and substantial ROI, balanced by near-term risk and volatility.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $7.68, with a min of $5.97 and a max of $10.55, and a projected ROI of 50.9%. The sentiment is BULLISH.
Forecasts indicate a bullish trajectory from 2028 onward, with the average price rising to $13.04 by 2040 and $27.24 by 2050, and ROIs of 156.1% by 2040 and 435.2% by 2050. The early years (2026–27) are neutral, so the longer-term outlook is favorable but not guaranteed.
Yes. The forecast shows a max of $10.55 in 2030, $10.81 in 2031, and $11.29 in 2032, with earlier 2029 max at $10.06. By 2030 the average is $7.68 and the sentiment turns bullish.
The current price is $5.09 and the market capitalization is $482.65M. The rank is 3097.
The 30-day range is from a low of $4.47 to a high of $5.79.
Valneva SE Community Discussion
0Share your Valneva SE price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.